Acumen exercises option for JCR technology
Acumen Pharmaceuticals (NASDAQ:ABOS) executed its exclusive option to develop and manufacture two Alzheimer's disease treatment candidates using the proprietary blood-brain barrier (BBB)-penetrating platform from JCR Pharmaceuticals (TSE:4552).




_1423491_640x360_2503940163566-640x360.webp&w=3840&q=75)
_1423491_640x360_2503937091749-640x360.webp&w=3840&q=75)



_1423448_640x360_2503928387723-640x360.webp&w=3840&q=75)
_1423439_640x360_2503936067547-640x360.webp&w=3840&q=75)
